NASDAQ:CTXR - Citius Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.45 -0.06 (-3.97 %) (As of 08/21/2018 04:00 PM ET)Previous Close$1.49Today's Range$1.45 - $1.4952-Week Range$1.12 - $5.49Volume5,425 shsAverage Volume371,129 shsMarket Capitalization$15.80 millionP/E RatioN/ADividend YieldN/ABeta4.8 Company ProfileAnalyst RatingsChartEarnings HistoryInsider TradesHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Receive CTXR News and Ratings via Email Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:CTXR CUSIPN/A Webwww.citiuspharma.com Phone908-967-6677 Debt Debt-to-Equity RatioN/A Current Ratio1.29 Quick Ratio1.29 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$2.66 per share Price / Book0.55 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-10,380,000.00 Net MarginsN/A Return on Equity-54.80% Return on Assets-49.55% Miscellaneous Employees7 Outstanding Shares10,680,000Market Cap$15.80 million Citius Pharmaceuticals (NASDAQ:CTXR) Frequently Asked Questions What is Citius Pharmaceuticals' stock symbol? Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR." When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work? Citius Pharmaceuticals shares reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split. How were Citius Pharmaceuticals' earnings last quarter? Citius Pharmaceuticals Inc (NASDAQ:CTXR) issued its quarterly earnings data on Tuesday, August, 14th. The company reported ($0.19) EPS for the quarter, topping the Zacks' consensus estimate of ($0.32) by $0.13. View Citius Pharmaceuticals' Earnings History. What price target have analysts set for CTXR? 1 brokers have issued twelve-month price objectives for Citius Pharmaceuticals' shares. Their predictions range from $11.00 to $11.00. On average, they anticipate Citius Pharmaceuticals' stock price to reach $11.00 in the next year. This suggests a possible upside of 643.2% from the stock's current price. View Analyst Price Targets for Citius Pharmaceuticals. What is the consensus analysts' recommendation for Citius Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Citius Pharmaceuticals. Who are some of Citius Pharmaceuticals' key competitors? Some companies that are related to Citius Pharmaceuticals include Alimera Sciences (ALIM), DiaMedica Therapeutics (DMCAF), Novelion Therapeutics (NVLN), Evofem Biosciences (EVFM), Helix Biopharma (HBPCF), Eyenovia (EYEN), Addex Pharmaceuticals (ADDXF), IntelGenx Technologies (IGXT), Vascular Biogenics (VBLT), Chiasma (CHMA), Humanigen (HGEN), Zosano Pharma (ZSAN), Novus Therapeutics (NVUS), Catabasis Pharmaceuticals (CATB) and Bellerophon Therapeutics (BLPH). Who are Citius Pharmaceuticals' key executives? Citius Pharmaceuticals' management team includes the folowing people: Mr. Leonard L. Mazur, Exec. Chairman & Sec. (Age 73)Mr. Myron Z. Holubiak, Pres, CEO & Director (Age 71)Mr. Jaime Bartushak, CFO & Chief Accounting Officer (Age 50)Mr. Gary F. Talarico, Exec. VP of Operations (Age 63)Mr. Andrew Scott, VP of Corp. Devel. Has Citius Pharmaceuticals been receiving favorable news coverage? Press coverage about CTXR stock has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Citius Pharmaceuticals earned a media and rumor sentiment score of 0.15 on Accern's scale. They also assigned news headlines about the company an impact score of 41.07 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Citius Pharmaceuticals. How do I buy shares of Citius Pharmaceuticals? Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Citius Pharmaceuticals' stock price today? One share of CTXR stock can currently be purchased for approximately $1.48. How big of a company is Citius Pharmaceuticals? Citius Pharmaceuticals has a market capitalization of $15.80 million. Citius Pharmaceuticals employs 7 workers across the globe. How can I contact Citius Pharmaceuticals? Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677. MarketBeat Community Rating for Citius Pharmaceuticals (NASDAQ CTXR)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 57 (Vote Outperform)Underperform Votes: 61 (Vote Underperform)Total Votes: 118MarketBeat's community ratings are surveys of what our community members think about Citius Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTXR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/21/2018 by MarketBeat.com StaffFeatured Article: Asset Allocation Models, Which is Right For You?